文献速递类风湿关节炎

接受JAK抑制剂治疗的韩国类风湿关节炎患者带状疱疹危险因素:巢式病例对照研究

Risk factors for herpes zoster in Korean patients with rheumatoid arthritis treated with JAK inhibitor: a nested case-control study.
PubMed 文献 · RMD Open · 2022-01-01

该研究基于韩国单中心前瞻性队列,纳入1147例接受靶向治疗的类风湿关节炎患者,按性别和年龄1:10匹配,选出61例带状疱疹病例和610例对照。条件logistic回归显示,JAK抑制剂使用未增加带状疱疹风险(OR 1.35,95%CI 0.70至2.61);既往靶向治疗≥3种和RA病程<10年是危险因素。在JAK抑制剂使用者中,高DAS28-ESR和既往靶向治疗≥3种是额外危险因素。

要点

  • JAK抑制剂使用未增加带状疱疹风险(OR 1.35,95%CI 0.70至2.61)。
  • 既往靶向治疗≥3种与带状疱疹风险升高相关(OR 5.29,95%CI 1.45至19.31)。
  • JAK抑制剂使用者中高DAS28-ESR与带状疱疹风险升高相关(OR 1.44,95%CI 1.06至1.97)。

核心结论

  • 在真实世界韩国RA患者中,既往靶向治疗种数而非JAK抑制剂使用被确定为带状疱疹发生的危险因素。
  • 高疾病活动度是JAK抑制剂使用者发生带状疱疹的额外危险因素。

研究设计与样本

  • 在韩国单中心接受靶向治疗的前瞻性RA队列中开展巢式病例对照研究,按性别和年龄1:10匹配。
  • 从1147例患者中选出61例带状疱疹病例和610例匹配对照。
  • 采用条件logistic回归分析JAK抑制剂使用对比bDMARD使用的带状疱疹风险,并调整多种因素。
  • 采用logistic回归分析识别JAK抑制剂使用者发生带状疱疹的其他危险因素。

主要发现

  • 调整其他因素后,JAK抑制剂使用未增加带状疱疹风险(OR 1.35,95%CI 0.70至2.61)。
  • RA病程<10年(OR 0.54,95%CI 0.30至0.97)和既往靶向治疗≥3种(OR 5.29,95%CI 1.45至19.31)与带状疱疹风险相关。
  • 在JAK抑制剂使用者中,高DAS28-ESR(OR 1.44,95%CI 1.06至1.97)和既往靶向治疗≥3种(OR 10.12,95%CI 1.92至53.49)为危险因素。

关键数值与推荐

  • JAK抑制剂使用对比bDMARD使用:OR 1.35(95%CI 0.70至2.61)。
  • RA病程<10年:OR 0.54(95%CI 0.30至0.97)。
  • 既往靶向治疗≥3种:OR 5.29(95%CI 1.45至19.31)。
  • JAK抑制剂使用者中高DAS28-ESR:OR 1.44(95%CI 1.06至1.97)。
  • JAK抑制剂使用者中既往靶向治疗≥3种:OR 10.12(95%CI 1.92至53.49)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the risk of herpes zoster (HZ) in Korean patients with rheumatoid arthritis (RA) receiving Janus kinase inhibitors (JAKis). METHODS: We performed a nested case-control study with 1:10 matching for sex and age using single-centre prospective cohorts of patients with RA receiving targeted therapy in Korea. Then we performed conditional logistic regression analyses to determine the risk associated with JAKi use compared with biologic disease-modifying antirheumatic drug (bDMARD) use, with adjusting for various factors. We also used logistic regression analysis to identify other risk factors for the development of HZ in JAKi users. RESULTS: From a total of 1147 patients, 61 cases and 610 matched controls were selected. In conditional logistic regression analysis, JAKi use did not increase the risk of HZ development (OR 1.35, 95% CI 0.70 to 2.61) after adjusting for other factors. Rather, duration of RA less than 10 years (OR 0.54, 95% CI 0.30 to 0.97) and having had three or more previous targeted therapies (OR 5.29, 95% CI 1.45 to 19.31) were risk factors for HZ. Among JAKi users, higher disease activity score 28-erythrocyte sedimentation rate (DAS28-ESR) (OR 1.44, 95% CI 1.06 to 1.97) was identified as a risk factor in addition to three or more previous targeted therapies (OR 10.12, 95% CI 1.92 to 53.49). CONCLUSIONS: The number of previous targeted therapies, but not JAKi use, was identified as a risk factor for HZ development in Korean patients with RA in a real-world setting. High disease activity was an additional risk factor for JAKi users.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Song YJ, Cho SK, Kim H, et al. Risk factors for herpes zoster in Korean patients with rheumatoid arthritis treated with JAK inhibitor: a nested case-control study. RMD Open. 2022. PMID: 35091461. doi:10.1136/rmdopen-2021-001892

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。